New Directions for the Treatment of Chronic Myeloid Leukaemia

Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–99 Kantarjian HM, Deisseroth A, Kurzrock R, et al. Review. chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691–703 Goldman JM. Management of chronic myeloid leukaemia. Blood Rev 1994; 8: 21–9 O’Brien SG, Goldman JM. Autografting in chronic myeloid leukaemia. Blood Rev 1994; 8: 63–69 Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532–8 Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–5 Allan NC, Richards SM, Shepherd PCA for the Medical Research Council’s Working Party for Therapeutic Trials in Adult Leukaemia. Interferon-α in the management of chronic myeloid leukaemia: benefit is not confined to those with cytogenetic response. Lancet. In press Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82: 398–407 Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975–84 Goldman JM, Biggs JC, Bortin MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–14 Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation [editorial]. Blood 1993; 82: 1954–6 Snyder DS, Negrin RS, O’Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84: 1672–9 Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235–8 Simonsson B, Oberg G, Bjoreman M, et al. Intensive treatment in order to minimise the Ph-positive clone in chronic myelogenous leukemia. Leuk Lymphoma 1992; 7 Suppl.: 55–7 De Fabritiis P, Sandrelli A, Meloni G, et al. Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment may necessitate delay in harvesting marrow cells for autografting. Bone Marrow Transplant 1990; 6: 247–51 Hoyle C, Gray R, Goldman J, et al. Autografting for patients with CML in chronic phase — an update. Br J Haematol 1994; 86: 76–81 McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–8 Reiffers J, Goldman JM, Meloni G, et al. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the EBMT Registry. Bone Marrow Transplant 1994; 14: 407–10 Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84: 724–32 Carella AM, Podesta M, Pollicardo N, et al. Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR— cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis [letter]. Leukemia 1994; 8: 212–3 Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. Ann Intern Med 1993; 119: 207–14 McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543–50 Anasetti C, Anderson G, Choo YS, et al. Marrow transplantation from unrelated donors for treatment of chronic myeloid leukemia [abstract no. 470]. Exper Hematol 1992; 20: 830